COMP <GO>
NKTR vs KARD // EV/EBITDA & P/E VALUATION
Nektar Therapeutics (NASDAQ) VS. Kardigan Inc. (NASDAQ) • 15-METRIC TALLY: NKTR 0
— KARD 2
■ METRIC PARITY
LAST: $39.18 (+1.63%) • MKT CAP: $1.34B
valuation
—
LAST: $14.31 (+4.22%) • MKT CAP: $1.34B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NKTR VS. KARD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NKTR | KARD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.60% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -43.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.7 | 48.1 | -13.37 | KARD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.34B | $1.34B | -$315.4K | KARD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NKTR REV | KARD REV | NKTR GROSS % | KARD GROSS % | NKTR FCF | KARD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $55.2M | $0 | 98.0% | — | -$208.7M | — |
| FY 2024 | $98.4M | — | 68.8% | — | -$177.2M | — |
| FY 2023 | $90.1M | — | — | — | -$192.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NKTR // BETA —
KARD // BETA —